Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

NCT05430828 · clinicaltrials.gov ↗

RECRUITING

Status

5000

Enrollment

OTHER

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Repatha (evolocumab); Praluent (alirocumab)

Sponsor

Federico II University